City
Epaper

India requires Rs 80,000 cr for vaccine distribution next year: SII

By IANS | Updated: December 19, 2020 13:05 IST

New Delhi, Dec 19 Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the ...

Open in App

New Delhi, Dec 19 Pune-based vaccine-maker Serum Institute of India, which has partnered with AstraZeneca to manufacture the Oxford-AstraZeneca vaccine, on Saturday said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year.

The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with comorbidities.

Three vaccine candidates - Serum Institute-Oxford's Covishield, Bharat Biotech's Covaxin and Pfizer vaccine are in the fray for emergency use authorization. The Central Drugs Standard Control Organisation

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

International90 Tibetan children's paintings displayed in Dharamshala restaurants to celebrate Dalai Lama's 90th birthday

HockeyBihar to host 12th Men's Asia Cup at Rajgir Hockey Stadium; CM Nitish Kumar unveils mascot and trophy

InternationalEuropean leaders, Zelensky to meet Trump in Washington

InternationalEgypt, Iran condemn Israeli plans to relocate Palestinians

Other SportsMaharaja Trophy: Shivamogga Lions - Mysore Warriors game ends in no result

Health Realted Stories

HealthBangladesh: One more person dies of dengue, 2025 toll rises to 105

HealthPrevention, not just medication, key to tackling obesity and diabetes: Jitendra Singh

HealthAyush seminar to boost ayurveda‑based paediatric healthcare

HealthIIT Kharagpur launches healthcare and technology school to train youth as health professionals

HealthNovel live type 1, 3 oral polio vaccines show promise in phase 1 trial